USP 800 compliance means following the safety standards in United States Pharmacopeia General Chapter <800>, a set of requirements designed to protect healthcare workers, patients, and the environment from exposure to hazardous drugs. The chapter covers every step of hazardous drug handling, from the moment a shipment arrives at a facility through receipt, storage, compounding, dispensing, administration, and disposal of both sterile and nonsterile products. Any facility that handles hazardous drugs, including hospitals, pharmacies, clinics, and veterinary practices, falls under its scope.
What Counts as a Hazardous Drug
USP <800> relies on the National Institute for Occupational Safety and Health (NIOSH) list to define which medications qualify as hazardous. NIOSH groups these drugs into three categories: antineoplastic drugs (chemotherapy agents), non-antineoplastic hazardous drugs, and drugs that primarily pose a reproductive risk. A drug lands on this list when it has properties like cancer-causing potential, organ toxicity at low doses, or the ability to harm fetal development.
Each facility is required to maintain its own internal list of hazardous drugs, reviewed regularly and built from the current NIOSH list. This matters because the specific precautions you need to take depend on which category a drug falls into. Antineoplastic drugs carry the strictest handling requirements, while reproductive-risk-only drugs may allow some flexibility through a documented risk assessment.
Who Enforces It
USP <800> is not enforced by a single national agency. Instead, enforcement typically falls to state boards of pharmacy and state occupational safety agencies. In Minnesota, for example, both the state OSHA program and the Board of Pharmacy share enforcement authority and can impose fines or civil penalties for violations. The practical result is that enforcement varies by state: some states have formally adopted USP <800> into their pharmacy regulations, while others reference it as a standard of practice without a specific adoption date. If you work in or manage a facility that handles hazardous drugs, your state board of pharmacy is the best source for understanding your specific compliance obligations.
PPE Requirements by Task
One of the most detailed sections of USP <800> involves personal protective equipment. The standard doesn’t simply say “wear gloves.” It specifies exactly what type of PPE is needed for each step of the medication handling process, and the requirements change depending on the task.
Gloves used for hazardous drug handling should be powder-free and meet ASTM standard D6978, which tests for resistance to permeation by chemotherapy drugs. For most tasks involving direct contact with hazardous drugs, two pairs of gloves are required. The first pair goes on before the gown, and the outer pair goes over the gown’s cuffs to create a sealed barrier.
Here’s how PPE requirements break down across common tasks:
- Sterile compounding (mixing IV chemotherapy, for example): two pairs of gloves, a protective gown, a cap, a surgical mask, and shoe covers.
- Unpacking and storing hazardous drug shipments: two pairs of gloves and a gown if the drugs aren’t sealed in protective plastic packaging.
- Administering liquid medications (IV, injection, bladder instillation): two pairs of gloves and a gown when there’s a risk of splashing.
- Handing a patient a hazardous tablet: one pair of gloves, no gown required.
- Handling contaminated bedding or patient waste: two pairs of gloves and a gown.
- Cleaning spills or broken containers: two pairs of gloves and a gown, particularly when powder or aerosol exposure is possible.
- Cleaning preparation rooms and hoods: two pairs of gloves and a gown.
Gowns must be disposable, lint-free, made of low-permeability fabric, have long sleeves with tight cuffs, and close in the back. During active compounding or administration shifts, gowns need to be changed every three and a half hours or at the midpoint of a shift, whichever comes first. This isn’t arbitrary: the fabric’s protective barrier degrades with time and exposure.
Designated Person and Training
Every facility must appoint a designated person who is qualified and trained to oversee hazardous drug safety. This person is responsible for developing handling procedures, ensuring the facility complies with USP <800> and applicable laws, and confirming that all personnel are competent in safe handling practices.
The designated person must also create and implement a formal training program. This program needs to describe what training is required, how often it happens, and how staff competency is evaluated. Training isn’t a one-time event. Personnel must demonstrate ongoing competency, which means periodic reassessment rather than simply completing an initial orientation. The specifics of the training schedule are set by each facility, but the expectation is that competency evaluations happen regularly enough to catch and correct unsafe habits before they lead to exposure.
Storage and Facility Design
USP <800> requires that hazardous drugs be stored separately from non-hazardous inventory to minimize the risk of accidental exposure. Storage areas need adequate ventilation to prevent drug vapors or particles from accumulating in the air. For facilities that compound hazardous drugs, the requirements become more specific: compounding must take place in a negative-pressure room with externally vented air, meaning air flows into the room rather than out of it, preventing contaminated air from reaching other parts of the facility.
These engineering controls represent one of the costlier aspects of compliance. Retrofitting an existing pharmacy to meet negative-pressure ventilation standards can require significant construction, which is one reason implementation has been a gradual process for many facilities.
Assessment of Risk
For certain hazardous drugs, particularly non-antineoplastic drugs and those that only pose a reproductive risk, USP <800> allows facilities to perform an Assessment of Risk. This is a formal, documented evaluation where a facility examines factors like the drug’s dosage form (a sealed tablet versus a powder that could become airborne), the volume handled, and the frequency of handling to determine whether alternative containment strategies are acceptable.
This flexibility does not apply to antineoplastic drugs, which must always be handled with the full set of engineering controls and PPE. The Assessment of Risk exists because treating every hazardous drug identically would be impractical. Handing a patient a single sealed hormone tablet, for instance, poses a fundamentally different exposure risk than reconstituting a vial of chemotherapy powder. The assessment must be documented, reviewed by the designated person, and updated when conditions change.
What Compliance Looks Like in Practice
For a facility working toward full USP <800> compliance, the process typically involves several overlapping steps: building and maintaining a hazardous drug list, appointing and training a designated person, auditing current PPE practices against the chapter’s requirements, evaluating whether storage areas and compounding rooms meet ventilation standards, creating a formal training and competency program, documenting Assessments of Risk where applicable, and establishing procedures for spill management and waste disposal.
The financial and operational burden varies widely. A small retail pharmacy that dispenses a handful of hazardous oral medications faces a much simpler path than a hospital cancer center that compounds hundreds of chemotherapy doses per week. But the core principle is the same across all settings: every person who touches a hazardous drug, from the technician who unpacks the box to the nurse who administers the dose, should be protected by a combination of engineering controls, proper PPE, and training that is documented and regularly reinforced.